Telomerase-active urine-derived stem cells: Regenerative solutions for aging

Aging is a complex process that leads to various pathologies and poses a significant socioeconomic challenge. Stem cell therapies offer a promising avenue for intervention, primarily through mechanisms like telomere maintenance and cellular rejuvenation. However, conventional stem cell sources often come with limitations such as invasive collection, ethical concerns, safety risks, and high costs, which impede their clinical application. Urine-derived stem cells (USCs), in contrast, present an appealing alternative for regenerative medicine. Uniquely, USCs contain two distinct populations: those with high telomerase activity (TA) and long telomeres, and those with low or undetectable TA. Notably, the unique presence of telomerase-active USCs provides a novel avenue for addressing telomere attrition, a primary hallmark of biological aging, and holds significant translational geroscience relevance. Unlike stem cells derived from bone marrow or adipose tissue, which lack TA, USCs are obtained non-invasively through routine urination, significantly reducing patient discomfort and ethical issues. Moreover, compared to induced pluripotent stem cells (iPSCs), USCs pose a lower risk of tumorigenicity and require less complex manipulation, simplifying their journey to clinical use. USCs demonstrate robust proliferative capacity, broad differentiation potential, and enhanced safety profiles, making them well-suited for addressing age-related tissue degeneration and functional decline. Preclinical studies have already shown their effectiveness in mitigating age-related disorders and facilitating personalized medicine through disease modeling and drug discovery. While USC-based therapies are still in early development, their unique properties-especially the presence of USCs with robust telomerase activity-position them as an accessible and promising platform for regenerative medicine to combat age-related decline.